Ciprofloxacin in multi-resistant infections in childhood: An audit by Khan, D M & Bhutta, Z A
eCommons@AKU
Department of Paediatrics and Child Health Division of Woman and Child Health
June 1995
Ciprofloxacin in multi-resistant infections in
childhood: An audit
D M. Khan
Aga Khan University
Z A. Bhutta
Aga Khan University, zulfiqar.bhutta@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr
Part of the Pediatrics Commons
Recommended Citation
Khan, D. M., Bhutta, Z. A. (1995). Ciprofloxacin in multi-resistant infections in childhood: An audit. Journal of Pakistan Medical
Association, 45(6), 147-150.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/433
Ciprofloxacin in Multi-Resistant Infections in Childhood: An
Audit
Pages with reference to book, From 147 To 150 
Danyal Mushtaq Khan, Zulfiqar A. Bhutta ( Department of Paediatrics, The Aga Khan University, Karachi. ) 
Abstract 
Ciprofloxacm is a new orally administrable fluoroquinolones, with considerable efficacy against multi-
resistant organisms. Its use in the paediatric age group however, is controversial because of the risk of
potential articular toxicity. We retrospectively reviewed ciprofloxacin usage over a 32 week periods
(June, 1991- September, 1993) in paediatric inpatients at The Aga Khan University Hospital.
Ciprofloxacin was used in 21 cases, singly in 11 (52%) and in combination with other antibiotics in a
further 10 (48%). The response to therapy was adjudged as ‘good’ or ‘fair’ in 13(62%) cases.
Ciprofloxacin was the only sensitive antibiotic in 4(19%) and resistance to it was detected in another
4(19%) cases. Despite all efforts, adequate follow-up could only be achieved in a third of the patients.
Although no toxic or side effects were detected, in view of poor follw-up and emergence of
ciprofloxacin resistant strains, our experience highlights the need to regulate ciprofloxacin use in the
paediatric age group (JPMA 45:147, 1995).
Introduction 
Ciprofloxacin (CPX) is a new synthetic fluorinated carboxyquinolone with broad spectrum activity
against aerobic gram positive organisms especially methicillin-resistant staphylococci and gram
negative organisms such as Klebsiella, Enterobacter, Pseudomonas and Salmonella species1,2. CPX has
thus been used extensively in adults for infections with resistant organisms. It offers considerable
advantages over other antibiotics because of its broad spectrum, effective tissue penetration and ease of
oral administration. In the developing world scenario, the emergence of multi-resistant strains of
several organisms has begun to pose major health problems3. In view of the prohibitive costs of newer
parenteral antibiotics, this has led to widespread quinolone and CPX usage in these countries, for
reasons of cost and ease of ambulatory therapy.
The safety of CPX in the pediatric age group however, is controversial, as experiments with juvenile
animals have shown quinolones to be toxic to weight bearing joints4-8. However, CPX has been used
recently in multi-drug resistant typhoidal infections in children9 with considerable benefits, Its use
therefore, in other paediatnc severe infections has also begun to increase. The Aga Khan University
Hospital (AKUH) is a 400 bed teaching hospital with a 80 bed pediatric ward and a 15 bed Neonatal
Intensive Care Unit. At AKUH, CPX is not used routinely in the pediatric age group, but canbe
prescribed under special circumstances, at the discretion of the attending physician. This audit of CPX
use in the pediatric age group was conducted with a view to determine the frequency of CPX usage, its
efficacy, patterns of resistance and potential side effects.
Materials and Methods 
This is a retrospective case review of all hospitalized children (<16 years) at AKUH, who were treated
as inpatients with CPX for _24 hours, over a 32 months period (January, 1991 - September, 1993).The
charts were analyzed forpatient characteristics, presenting complaints, diagnosis, microbiological data,
indications forCPX usage, side effects, toxicity or interaction with other drugs, response to therapy,
final outcome and follow- up. Response to therapy was judged by defervescence, loss of toxicity and
the eradication of organisms as proved on negative cultures. Defervescence was defined as body
temperature remaining <37.7°C for _24 hours. Resistance was determined by the disc diffusion method
and graded according to the zone of inhibition10. Minimal inhibitory concentrations of antibiotic were
determined in selected cases by standard methods11.
Results 
A total of 21 children (15 boys and 6 girls) received intravenous and oral CPX over this period, alone
(52%) or in combination with other antibiotics (48%). The mean age was 13 months witha range of day
to 12 years. Nineteen (91%) of the patients were infants, out of whom 10 (48%) were neonates.
Table I shows the diagnoses of the children who received CPX.
Table II describes the microbiological spectmm of isolates in these cases, while the resistance pattern to
various antibiotics is shown in Table III.
There was one patient with an infected ventriculoperitoneal (VIP) shunt, in whom no organism could
be isolated from either blood orCSF cultures. Resistance to CPX was detected in four patients. Two
(10%) of the organisms showed full resistance to CPX at initial presentation One of the patients had
meningitis with enterococcus, while the other had pneumonia with enterobacter cloacae. One patient
with a VP shunt infection with staphylococcus epidermidis, was initially sensitive to CPX, but
developed resistance after 5 days of therapy. One patient with salmonella paratyphi B meningitis also
showed partial resistance to CPX on MIC determination.
CPX was initially started empirically in 5 cases (24%). In one of these cases with an infected VP shunt,
the organism could not be isolated, while in another child with meningitis the organism isolated at the
referring hospital was knownto be Serratia, but no sensitivities were available. In the other cases CPX
was initiated alone, or in combination with other antibiotics, as the patients were critically ill. In the
rest of the 16 cases (76%), CPX therapy was initiated after the availability of the culture/sensitivity
results. In 4 (19%) of the cases, the organisms were resistant to all antibiotics except CPX. These
included two cases of Klebsiella sepsis and one case each of Salmonella paratyphi sepsis and
enterobacter sepsis. In another 6 cases (29%), CPX was used when there was no clinical improvement
on other sensitive antibiotics. In the rest of the patients CPX was used as the alternative sensitive
antibiotics did not have good CSF penetration.
The mean duration of therapy was 11 days with a range of 2 to 21 days. The response to therapy was
judged to be ‘good’ in 10 patients (48%) and ‘fair’ in another 3 patients (14%). The response was
‘poor’ in 6 patients (28%) and the antibiotic had to be changed, while in 2 (10%) of the patients the
efficacy could not be determined from the records. The meantime-to-clinical response when efficacy
was goodor fair was 2.5 days, with a range of ito 5 days. There was only one death (5%) of a newborn
with pseudomonas pneumonia who was receiving multiple antibiotics.
All patients were given outpatient appointments on discharge from AKUH. However, of the twenty
survivors, seven (3 5%) were being followed-up to date, with an average duration of 7 months. Eight
(40%) of the patients returned initially, but were lost to follow-up afteran average duration of 2 months,
while five (25%) failed to return after discharge. No toxic or side effects such asjoint pain,joint
swelling, skin rashes, abdominal discomfort, headaches, dizziness, or signs of CNS dysfunction were
noted at any stage.
Discussion 
Development of resistance is a major problem with antibiotic therapy in developing countries where
inappropriate antibiotic use is rampant and over-the-counter antibiotics are freely available. CPX is a
new antibiotic that acts by inhibiting DNA gyrase, an enzy me which is essential for replication in
prokaryocytes1,6,12. CPX has broad spectrum bactericidal activity, effective tissue penetration and can
be administered orally. It is therefore, not surpnsing that CPX has become an attractive choice in the
developing world for treating multidrug resistant infections. Development of resistance to CPX is slow
and usually develops by altering the membrane proteins or the structure of DNA gyrase (especially its
subunit A proteins) 13-15. There have been some reports of CPX resistance in methicillin resistant
staphylococcus and pseudomonas recently16-23. There were 4 cases in our series that were treated with
CPX initially but the organism was subsequently found to be resistant. Two organisms (enterococcus
and enterobacter) were fully resistant, one (salmonella paratyphi) was partially resistant, while one
organism (staphylococcus epidermidis) was initially sensitive, but resistance developed to CPX on
therapy.
The efficacy of CPX in several series of children with bacteremic infections has ranged from
94~100%12,24,25. CPX has been shown to be more effective than conventional antibiotics in the
treatment of typhoid and salmonellosis6,8,26,27. The response to therapy to CPX in our series is
however, lower than that reported by other workers. This could be related to a higher proportion of
complicated referral cases at AKUH as compared to other hospitals. In our audit, CPX was clinically
efficacious in 50% of the 6 meningitis patients and in all of the 3 patients with infected VP shunts. CPX
penetration into CSF is approximately20- 30%28 and is enhanced with meningeal inflammation29.
Schonwald found its efficacy in gram negative bacillary meningitis to be 90%23. CPX has been shown
to cause damage to cartilage/joints in experimental animals3,5-8. This effect however, may be species
specific. Nalidixic acid also causes cartilage damage in animals but inspite of extensive pediatric usage,
no such effect has been reported in children. CPX has been used in children in the West, mostly for
exacerbations of resistant pseudomonas infections in cystic fibrosis22, but todate no overtcartilage
damage has been reported mover 1500 patients treated worldwide3,5,12,24. There have been two
published reports ofjoint symptoms on CPX therapy, a 16 year old girl and a 10 1ear old boy, who
developed joint pain on CPX therapy30,31 The symptoms however, resolved in both cases on stopping
the antibiotic. In our experience todate, no significant side effects or toxicity were observed during
therapy and in those followed up. CPX related chondrotoxicity may be acute and show up
withindaysofstartingthernpy,butitmay sometimes eventake long as to manifest. On a cautionary note,
despite all efforts, our follow- up was incomplete in 65% of the cases. This underscores the difficulty in
securing longterm follow-up in similar circumstances in the developing world. Our data indicates that
CPX usage can be life saving in many suspected/proven multidrug resistant infections in children.
However, the recent emergence of drug resistance to CPX and the poor follow-up in our environment,
highlights the urgent need to regulate and restrict its widespread pediatric use and ‘over-the- counter’
sales. We recommend that CPXbe used in children only for life threatening infections orwhen all
alternative agents have failed, atleast until larger controlled clinical trials determine its efficacy and
adverse effects in this age group.
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